Dasatinib for the treatment of Philadelphia chromosome-positive leukaemias

Expert Opinion on Investigational Drugs

Volumn 16, Issue 5, 2007, Pages 679-687

  Jabbour, Elias ^a   Cortes, Jorge ^a   Kantarjian, Hagop ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Chronic myeloid leukaemia; Dasatinib; Imatinib intolerance; Imatinib resistance; Philadelphia chromosome positive acute lymphoblastic leukaemia

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; CYTARABINE; DASATINIB; DIURETIC AGENT; IMATINIB; PROTEIN KINASE LYN; STEROID; TOLTERODINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; CANCER GROWTH; CARDIOTOXICITY; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CYTOGENETICS; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FACE EDEMA; FATIGUE; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; LEUKEMIA; LEUKOPENIA; MUSCLE CRAMP; NAUSEA; NEUTROPENIA; NONHUMAN; PERIPHERAL EDEMA; PHILADELPHIA CHROMOSOME POSITIVE CELL; PLEURA EFFUSION; REVIEW; SKIN EDEMA; STEM CELL TRANSPLANTATION; THORACOCENTESIS; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; HUMANS; LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; THIAZOLES; TREATMENT OUTCOME;

EID: 34248204301     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.16.5.679     Document Type: Review

References (64)

1. JEMAL A, SIEGEL R, WARD E et al.: Cancer statistics, 2006. CA Cancer J. Clin. (2006) 56(2):106-130.
2. MUGHAL TI, GOLDMAN JM: Chronic myeloid leukemia: why does it evolve from chronic phase to blast transformation? Front. Biosci. (2006) 11:198-208.
3. QUINTAS-CARDAMA A, CORTES JE: Chronic myeloid leukemia: diagnosis and treatment. Mayo Clin. Proc. (2006) 81(7):973-988.
4. FADERL S, KANTARJIAN HM, TALPAZ M: Chronic myelogenous leukemia: update on biology and treatment. Oncology (1999) 13(2):169-180.
5. BARNES DJ, MELO JV: Cytogenetic and molecular genetic aspects of chronic myeloid leukaemia. Acta Haematol. (2002) 108(4):180-202.
6. ROWLEY JD: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature (1973) 243(5405):290-293.
7. MARTINELLI G, SOVERINI S, ROSTI G, CILLONI D, BACCARANI M: New tyrosine kinase inhibitors in chronic myeloid leukemia. Haematologica (2005) 90(4):534-541.
8. DEININGER M, BUCHDUNGER E, DRUKER BJ: The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood (2005) 105(7):2640-2653.
9. SCHINDLER T, BORNMANN W, PELLICENA P, MILLER WT, CLARKSON B, KURIYAN J: Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science (2000) 289(5486):1938-1942.
10. BUCHDUNGER E, CIOFFI CL, LAW N et al.: Abl protein-tyrosine kinasc inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J. Pharmacol. Exp. Ther. (2000) 295(1):139-145.
11. DRUKER BJ, TALPAZ M, RESTA DJ et al.: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. (2001) 344(14):1031-1037.
12. KANTARJIAN HM, CORTES J, O'BRIEN S et al.: Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood (2002) 99(10):3547-3553.
13. KANTARJIAN HM, O'BRIEN S, CORTES JE et al.: Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood (2002) 100(5):1590-1595.
14. KANTARJIAN H, SAWYERS C, HOCHHAUS A et al.: Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N. Engl. J. Med. (2002) 346(9):645-652.
15. KANTARJIAN HM, TALPAZ M, O'BRIEN S et al.: Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-α: follow-up results. Clin. Cancer Res. (2002) 8(7):2177-2187.
16. SAWYERS CL, HOCHHAUS A, FELDMAN E et al.: Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a Phase II study. Blood (2002) 99(10):3530-3539.
17. TALPAZ M, SILVER RT, DRUKER BJ et al.: Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a Phase II study. Blood (2002) 99(6):1928-1937.
18. O'BRIEN SG, GUILHOT F, LARSON RA et al.: Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med. (2003) 348(11):994-1004.
19. DRUKER BJ, GUILHOT F, O'BRIEN S, LARSON RA: Long-term benefits of imatinib (IM) for patients newly diagnosed with chronic myelogenous leukemia in chronic phase (CML-CP): the 5-year update from the IRIS study. J. Clin. Oncol. (2006) 24(18S):338s (Abstract 6506).
20. KERKELÄ R, GRAZETTE L, YACOBI R et al.: Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat. Med. (2006) 12(8):908-916.
21. LITZOW MR: Imatinib resistance: obstacles and opportunities. Arch. Pathol. Lab. Med. (2006) 130(5):669-679.
22. HOCHHAUS A, LA ROSEE P: Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance. Leukemia (2004) 18(8):1321-1331.
23. LAHAYE T, RIEHM B, BERGER U et al.: Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up. Cancer (2005) 103(8):1659-1669.
24. NATIONAL COMPREHENSIVE CANCER NETWORK: Clinical Practice Guidelines in Oncology - Chronic Myelogenous Leukemia (2007) version 1.
25. GRATWOHL A: The role of allogeneic stem cell transplantation for chronic myeloid leukemia. Haematology Eur. Haematol. Assoc. Educ. Program (2006):98-102.
26. GORRE ME, MOHAMMED M, ELLWOOD K et al.: Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science (2001) 293(5531):876-880.
27. HOCHHAUS A, KREIL S, CORBIN AS et al.: Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia (2002) 16(11):2190-2196.
28. ILLMER T, SCHAICH M, PLATZBECKER U et al.: P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate. Leukemia (2004) 18(3):401-408.
29. THOMAS J, WANG L, CLARK RE, PIRMOHAMED M: Active transport of imatinib into and out of cells: implications for drug resistance. Blood (2004) 104(12):3739-3745.
30. LARGHERO J, LEGUAY T, MOURAH S et al.: Relationship between elevated levels of the α1 acid glycoprotein in chronic myelogenous leukemia in blast crisis and pharmacological resistance to imatinib (Gleevec) in vitro and in vivo. Biochem. Pharmacol. (2003) 66(10):1907-1913.
31. LE COUTRE P, KREUZER KA, NA IK et al.: Determination of α-1 acid glycoprotein in patients with Ph+ chronic myeloid leukemia during the first 13 weeks of therapy with STI571. Blood Cells Mol. Dis. (2002) 28(1):75-85.
32. LIONBERGER JM, WILSON MB, SMITHGALL TE: Transformation of myeloid leukemia cells to cytokine independence by BCR-ABL is suppressed by kinase-defective Hck. J. Biol. Chem. (2000) 275(24):18581-18585.
33. DONATO NJ, WU JY, STAPLEY J et al.: BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood (2003) 101(2):690-698.
34. DAI Y, RAHMANI M, COREY SJ, DENT P, GRANT S: A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2. J. Biol. Chem. (2004) 279(33):34227-34239.
35. DANHAUSER-RIEDL S, WARMUTH M, DRUKER BJ, EMMERICH B, HALLEK M: Activation of Src kinases p53/56lyn and p59hck by p210bcr/abl in myeloid cells. Cancer Res. (1996) 56(15):3589-3596.
36. WARMUTH M, BERGMANN M, PRIESS A, HAUSLMANN K, EMMERICH B, HALLEK M: The Src family kinase Hck interacts with BCR-ABL by a kinase-dependent mechanism and phosphorlyates the Grb2-binding site of Bcr. J. Biol. Chem. (1997) 272(52):33260-33270.
37. ERNST TJ, SLATTERY KE, GRIFFIN JD: p210Bcr/Abl and p160v-Abl induce an increase in the tyrosine phosphorylation of p93c-Fes. J. Biol. Chem. (1994) 269(8):5764-5769.
38. LIONBERGER JM, SMITHGALL TE: The c-FES protein-tyrosine kinase suppresses cytokine-independent outgrowth of myeloid leukaemia cells induced by BCR-ABL. Cancer Res. (2000) 60(4):1097-1103.
39. KANTARJIAN HM, TALPAZ M, O'BRIEN S et al.: Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood (2003) 101(2):473-475.
40. KANTARJIAN HM, TALPAZ M, O'BRIEN S et al.: High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood (2004) 103(8):2873-2878.
41. SHAH NP: Loss of response to imatinib: mechanisms and management. Haematology Am. Soc. Haematol. Educ. Program (2005):183-187.
42. LOMBARDO LJ, LEE FY, CHEN P et al.: Discovery of N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin- l-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J. Med. Chem. (2004) 47(27):6658-6661.
43. SCHITTENHELM MM, SHIRAGA S, SCHROEDER A et al.: Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res. (2006) 66(1):473-481.
44. LEE FY, LOMBARDO L, CAMUSO A et al.: BMS-354825 potently inhibits multiple selected oncogenic tyrosine kinases and possesses broad-spectrum antitumor activities in vitro and in vivo. Proc. Am. Assoc. Cancer. Res. (2005) 46:675 (Abstract)
45. TOKARSKI JS, NEWITT JA, CHANG CY et al.: The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res. (2006) 66(11):5790-5797.
46. SHAH NP, TRAN C, LEE FY, CHEN P, NORRIS D, SAWYERS CL: Overriding imatinib resistance with a novel ABL kinase inhibitor. Science (2004) 305(5682):399-401.
47. O'HARE T, WALTERS DK, STOFFREGEN EP et al.: In vitro activity of BCR-ABL inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res. (2005) 65(11):4500-4505.
48. SAWYERS CL, SHAH NP, KANTARJIAN HM et al.: Hematologic and cytogenetic responses in imatinib-resistant chronic phase chronic myeloid leukemia patients treated with the dual SCR/ABL kinase inhibitor BMS-354825: results from a Phase I dose escalation study. Blood (2004) 11:4 (Abstract 1).
49. TALPAZ M, SHAH NP, KANTARJIAN H et al.: Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N. Engl. J. Med. (2006) 354(24):2531-2541.
50. HOCHHAUS A, KANTARJIAN H, BACCARANI M et al.: Dasatinib in patients with chronic phase chronic myeloid leukemia (CP-CML) who are resistant or intolerant to imatinib: results of the CA180013 'START C' study. J. Clin. Oncol. (2006) 24(18S):339s (Abstract 6508).
51. HOCHHAUS A, KANTARJIAN H, SHAH N et al.: A Phase II study of dasatinib in patients with chronic phase chronic myeloid leukemia who are resistant or intolerant to imatinib: results of the CA180013 START-C study. Haematologica (2006) 91(s1):170-171 Abstract 0467.
52. TALPAZ M, APPERLEY JF, KIM DW et al.: Dasatinib (D) in patients with accelerated phase chronic myeloid leukemia (AP-CML) who are resistant or intolerant to imatinib: results of the CA180005 'START-A' study. J. Clin. Oncol. (2006) 24(18S):343s (Abstract 6526).
53. GUILHOT F, APPERLEY JF, HOCHHAUS A et al.: Dasatinib (D) in patients (pts) with accelerated phase chronic myeloid leukemia (AP-CML) resistant or intolerant to imatinib: results of the CA180005 'START-A' study. Haematologica (2006) 91(s1):59 (Abstract 0159).
54. CORTES JE, KIM DW, ROSTI G et al.: Dasatinib (D) in patients (pts) with chronic myelogenous leukemia (CML) in myeloid blast crisis (MBC) who are imatinib-resistant (IM-R) or IM-intolerant (IM-I): Results of the CA180006 'START-B' study. J. Clin. Oncol. (2006) 24(18S):344s (Abstract 6529).
55. BACCARANI M, CORTES J, KIM DW et al.: Dasatinib in patient with chronic myelogenous leukemia in myeloid blast crisis (MBC) that is imatinib-resistant or IM-intolerant: results of the CA180006 'START-B' study. Haematologica (2006) 91(s1):56 (Abstract 0150).
56. COUTRE S, MARTINELLI G, DOMBRET H et al.: Dasatinib (D) in patients (pts) with chronic myelogenous leukemia (CML) in lymphoid blast crisis (LB-CML) or Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL) who are imatinib (IM)-resistant (IM-R) or intolerant (IM-I): the CA180015 'START-L' study. J. Clin. Oncol. (2006) 24(18S):344s (Abstract 6528).
57. OTTMANN O, MARTINELLI G, DOMBRET H et al.: Dasatinib in patients with chronic myelogenous leukemia in lymphoid blast crisis of Philadelphia chromosome positive acute lymphoblastic leukemia that is imatinib-resistant or intolerant: the CA180015 START-L study. Haematologica (2006) 91(s1):241 (Abstract 0653).
58. QUINTAS-CARDAMA A, KANTARJIAN H, JONES D et al.: Dynamics of molecular response to dasatinib (BMS-354825) in patients (pts) with chronic myelogenous leukemia (CML) resistant or intolerant to imatinib. J. Clin. Oncol. (2006) 24(18S):343s (Abstract 6525).
59. QUINTÁS-CARDAMA A, KANTARJIAN H, MUNDEN R et al.: Pleural effusions and dasatinib therapy. ASHASH Meeting Blood (2006) 108:2164 (Abstract).
60. SHAH NP, ROUSSELOT P, PASQUINI R et al.: Dasatinib (D) versus high dose imatinib (IM) in patients (pts) with chronic phase chronic myeloid leukemia (CP-CML) resistant to imatinib. Results of CA180017 START-R randomized trial. J. Clin. Oncol. (2006) 24(18S):338s (Abstract 6507).
61. KANTARJIAN H, ROUSSELOT P, PASQUINI D et al.: A randomized study of dasatinib versus escalated dose of imatinib in patients with chronic phase chronic myeloid leukemia resistant to imatinib: results of CA180017 START-R study. Haematologica (2006) 91(s1):170 (Abstract 0465).
62. CORTES J, TALPAZ M, O'BRIEN S et al.: Molecular responses in patients with chronic myelogenous leukemia in chronic phase created with imatinib mesylate. Clin. Cancer Res. (2005) 11(9):3425-3432.
63. WANG L, PEARSON K, FERGUSON JE, CLARK RE: The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukaemia. Br. J. Haematol. (2003) 120(6):990-999.
64. BURGESS MR, SKAGGS BJ, SHAH NP et al.: Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance. Proc. Natl. Acad. Sci. USA (2005) 102(9):3395-3400.